Tri-B
1. Disclaimer
This information is provided for educational and informational purposes only and is not a substitute for the current package leaflet, professional prescribing information, or advice from a qualified healthcare professional. Product composition, indications, dosage recommendations, excipients, regulatory status, and availability may change, and the information below should not be used as an independent basis for diagnosis or treatment.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
2. Summary
Tri-B is a vitamin B-complex medicinal product marketed in Egypt by The NILE Co. for Pharmaceuticals and Chemical Industries. Current Egyptian market listings identify two formulations under the Tri-B name: Tri-B 20 tablets, containing vitamins B1, B6, B12 and folic acid; and Tri-B I.M. 3 double ampoules, containing vitamins B1, B6 and B12 for intramuscular administration.
The preparation is primarily relevant to the prevention or treatment of documented vitamin deficiency and to conditions in which supplementation with B vitamins is considered appropriate. It should not be assumed that every neurological or painful condition benefits from vitamin supplementation in the absence of deficiency or an appropriate clinical indication.
The tablet formulation contains a relatively high dose of vitamin B6 (125 mg/tablet) and folic acid (5 mg/tablet); therefore, prolonged or unsupervised use is inappropriate, particularly when other vitamin B6- or folic-acid-containing products are also being taken. High cumulative vitamin B6 exposure can cause peripheral neuropathy.
3. Brand Name
Tri-B
Current Egyptian market listings include:
- Tri-B 20 Tab
- Tri-B I.M. 3 Double Amp
4. Category
Vitamin B-complex preparation / Vitamins
The injectable product is classified in current Egyptian market listings under Vitamin B.
5. Active Ingredient
Tri-B Tablets — each tablet contains
- Vitamin B1 (Thiamine): 125 mg
- Vitamin B6 (Pyridoxine): 125 mg
- Vitamin B12 (Cobalamin/Cyanocobalamin): 125 mcg
- Folic acid (Vitamin B9): 5 mg
Tri-B I.M. Double Ampoule
Each double ampoule consists of:
Ampoule 1
- Vitamin B1 (Thiamine): 100 mg
- Vitamin B6 (Pyridoxine): 40 mg
Ampoule 2
- Vitamin B12 (Cyanocobalamin): 1000 mcg
Important correction: the old text's “Vitamin B12 125 mg” is incorrect. The tablet strength is 125 mcg, not 125 mg.
6. Pharmaceutical Form & Strength
Tablets
- Oral tablets
- Pack size currently listed: 20 tablets
- Each tablet: B1 125 mg + B6 125 mg + B12 125 mcg + folic acid 5 mg.
Injection
- Intramuscular injection
- A double ampoule consists of two 1 mL ampoules, one containing B1/B6 and the other B12.
- The currently listed Egyptian presentation is 3 double ampoules, corresponding to 6 ampoules total.
7. Manufacturer & Marketing Authorization Holder
Manufacturer: The NILE Co. for Pharmaceuticals and Chemical Industries, Cairo, Egypt. Current Egyptian listings identify EL NILE as the manufacturer.
Marketing Authorization Holder: No separately identified current MAH was located in the accessible sources reviewed. The manufacturer should therefore not automatically be described as a separate MAH without confirmation from the current Egyptian regulatory documentation.
8. Mechanism of Action
Tri-B does not act through a single receptor or pharmacological target. Its effects are related to the physiological and biochemical functions of its vitamin components.
Vitamin B1 (thiamine) is converted to thiamine pyrophosphate, an essential coenzyme in carbohydrate metabolism and in the oxidative decarboxylation of alpha-keto acids.
Vitamin B6 (pyridoxine) is converted primarily to pyridoxal-5-phosphate, a coenzyme involved in numerous reactions, particularly amino-acid metabolism, transamination and decarboxylation.
Vitamin B12 (cobalamin) is required for normal DNA synthesis, red-cell formation and maintenance of normal neurological function; it participates in methionine and other metabolic pathways.
Folic acid is converted into biologically active folate cofactors involved in one-carbon transfer reactions required for DNA synthesis and normal cell division and erythropoiesis.
The combination therefore functions primarily by correcting or preventing deficiencies of these vitamins rather than by producing a specific analgesic, anti-inflammatory or antimicrobial pharmacological effect.
9. Spectrum of Activity
Not applicable.
Tri-B is a vitamin preparation and is not an antibacterial, antiviral, antifungal or antiparasitic medicine. It therefore has no conventional antimicrobial spectrum of activity.
10. Pharmacokinetics
Pharmacokinetics differ substantially among the individual vitamins.
After oral administration, the B vitamins and folic acid are absorbed through the gastrointestinal tract and subsequently distributed and metabolized according to their individual biochemical pathways.
Vitamin B12 has particularly distinctive absorption characteristics. Normal absorption from food depends on gastric processing and intrinsic factor, whereas high-dose supplemental B12 can also undergo a smaller fraction of passive absorption. Vitamin B12 is transported bound to specific proteins, stored predominantly in the liver, and excess absorbed vitamin can be excreted in the urine.
After intramuscular administration, the injectable vitamins bypass gastrointestinal absorption. Intramuscular cyanocobalamin is rapidly absorbed; plasma concentrations rise rapidly after injection, and the vitamin is transported to tissues with substantial hepatic storage. A substantial proportion of an injected dose can subsequently appear in the urine.
Because Tri-B contains several different vitamins and two different dosage forms, the simple statement in the old text that the entire product is “metabolized in the liver and excreted in urine” is an oversimplification and should not be retained as a general pharmacokinetic description.
11. Indications
The principal contemporary rationale for this type of preparation is prevention or treatment of vitamin B-group and/or folate deficiency when supplementation is clinically indicated.
Historically reproduced Tri-B information also lists use in:
- Painful neuropathies and neuralgia, including trigeminal neuralgia
- Polyneuritis and certain forms of neuritis
- Neuromuscular disorders associated with vitamin deficiency
- Certain macrocytic or megaloblastic anemias associated with vitamin deficiency
- Deficiency states following malabsorption or gastrectomy
- Pellagra and pernicious anemia
Older product material additionally listed pregnancy-related neuritis and vomiting of pregnancy. These historical indications should not be interpreted as evidence that Tri-B is a first-line treatment for modern clinical management of pregnancy-related vomiting or every neurological pain syndrome. Treatment should be based on the underlying diagnosis and current clinical guidance.
Vitamin replacement is particularly relevant when a deficiency is documented or strongly suspected. B-vitamin supplementation should not replace appropriate investigation of neuropathy, anemia, visual symptoms or other neurological disorders.
12. Administration
Tablets
The historical Tri-B product information states:
1–2 tablets daily or as directed by the physician.
A more recent Egyptian pharmacy listing gives a different dosing statement, demonstrating that online secondary sources are not sufficiently consistent to establish a single current dosage regimen.
Because the available current sources do not provide a verified current manufacturer dosing leaflet, the current package leaflet and prescriber instructions should take precedence rather than relying on an old online dosage statement.
Intramuscular injection
The product is intended for intramuscular administration.
Historical product information states that the contents of Ampoule 1 and Ampoule 2 are mixed and injected intramuscularly, traditionally described as daily or according to the physician's instructions.
The injection should be administered only by an appropriately trained healthcare professional using aseptic technique.
13. Method of Preparation
For the double-ampoule injection:
- The contents of Ampoule 1 (vitamin B1 + B6) and Ampoule 2 (vitamin B12) are mixed immediately before administration, consistent with the historical product instructions.
- The resulting preparation is administered by intramuscular injection.
- No additional diluent should be introduced unless specifically required by the current manufacturer instructions.
- The preparation should be inspected for abnormal particles, discoloration or container damage before administration.
The exact compatibility and preparation procedure should always follow the current package leaflet supplied with the product.
14. Contraindications
- Known hypersensitivity to thiamine, pyridoxine, cyanocobalamin, folic acid, or any other component of the relevant formulation.
- Previous serious hypersensitivity or anaphylactic reaction associated with parenteral thiamine or another component is a major reason to avoid re-exposure.
The old statement that Tri-B is simply “not used to treat megaloblastic anemia of pregnancy” is not an adequate modern contraindication statement. Rather, the cause of megaloblastic anemia must be established, especially because folic acid can improve hematologic abnormalities in vitamin B12 deficiency while neurological injury may continue.
15. Warnings & Precautions
Vitamin B6-associated peripheral neuropathy
This is one of the most important safety issues for the tablet formulation.
Each tablet contains 125 mg of vitamin B6, which is a high supplemental dose. Prolonged or repeated exposure to vitamin B6 can cause sensory peripheral neuropathy, including tingling, burning, numbness and other sensory disturbances. Regulatory safety reviews have documented neuropathy even at doses below 50 mg/day in some individuals, particularly when multiple B6-containing products are combined.
Patients should therefore avoid combining Tri-B with other vitamin B6-containing supplements unless specifically advised by a healthcare professional.
Hypersensitivity to injectable thiamine
Parenteral thiamine can rarely produce severe hypersensitivity reactions, including life-threatening anaphylaxis. This risk is particularly relevant to injectable treatment and has been documented with repeated parenteral exposure.
Folic acid and vitamin B12 deficiency
The tablet contains 5 mg of folic acid, a pharmacological rather than routine nutritional dose. High-dose folic acid can correct the anemia associated with vitamin B12 deficiency while failing to correct the underlying neurological injury, potentially delaying recognition of B12 deficiency.
Diagnostic evaluation
Persistent neuropathy, anemia, weakness, gait abnormalities, sensory changes or other neurological symptoms should not automatically be attributed to vitamin deficiency without appropriate medical assessment.
16. Drug Interactions
Levodopa
Vitamin B6 can increase the peripheral decarboxylation of levodopa, reducing its effectiveness when levodopa is administered without a peripheral decarboxylase inhibitor such as carbidopa. The old statement that B6 must simply be “avoided in all patients receiving levodopa” is therefore overly broad. Combination therapy containing carbidopa substantially changes this interaction.
Metformin
Metformin can reduce vitamin B12 absorption and may lower serum vitamin B12 concentrations during prolonged use.
Gastric acid-suppressing medicines
Long-term treatment with gastric acid inhibitors can impair absorption of food-bound vitamin B12 and contribute to deficiency.
Antiepileptic medicines and folic acid
Folic acid can interact with several antiseizure medicines, including phenytoin, phenobarbital and some other antiepileptic agents. Conversely, these medicines may reduce folate concentrations. The old statement that folic acid “should not be given” with these drugs is too absolute; concurrent use requires clinical monitoring and individualized management.
Sulfasalazine
Sulfasalazine can reduce folate absorption.
Pyridoxine-related interactions
Vitamin B6 can interact with medicines such as cycloserine, and some antiepileptic medicines can affect vitamin B6 status.
Colchicine
Long-term colchicine treatment can interfere with vitamin B12 absorption in susceptible patients. This interaction should be considered when evaluating unexplained B12 deficiency, but the old wording implying that colchicine invariably causes megaloblastic anemia should not be retained.
17. Side Effects
Possible adverse effects include:
- Nausea or other gastrointestinal symptoms
- Skin reactions or rash
- Hypersensitivity reactions
- Injection-site pain, tenderness or induration
- Rare but serious allergic or anaphylactic reactions following parenteral thiamine
- Peripheral sensory neuropathy with excessive or prolonged vitamin B6 exposure, which is particularly relevant to the 125 mg/tablet formulation.
Any new tingling, burning, numbness, balance problems or worsening sensory symptoms during prolonged use should prompt medical review.
18. Use in Special Populations
Pregnancy
The historical product literature mentions pregnancy-related indications, but the tablet contains 5 mg folic acid and 125 mg vitamin B6 per tablet, so it should not be treated as an ordinary prenatal multivitamin.
Folic acid is essential during pregnancy, but the appropriate dose depends on the indication and individual risk factors. High-dose folic acid should be used when clinically indicated rather than automatically self-administered. High-dose supplementation can also obscure the hematologic manifestations of vitamin B12 deficiency.
Lactation
B vitamins can be present in breast milk. Use during breastfeeding should be based on clinical need and the current formulation's labeling, particularly because the tablet contains a high dose of vitamin B6.
Pediatrics
The safety and appropriateness of the high-dose tablet formulation or injectable preparation in children should be determined by a healthcare professional. Injectable products containing preservatives such as benzyl alcohol require particular caution in neonates and certain pediatric populations; the current product-specific labeling should be consulted.
Renal or hepatic impairment
There is insufficient product-specific current information available in the sources reviewed to provide a separate Tri-B dosage adjustment recommendation. Patients with significant renal or hepatic disease should use the product under professional supervision.
19. Storage Conditions
Current product packaging and Egyptian market images indicate:
- Store below 25°C.
- Keep in a dry place and away from light.
- Keep out of the reach of children.
The product should remain in its original packaging until use and should not be used after the expiry date.
20. Additional Sections
Key formulation distinction
Tri-B tablets and Tri-B I.M. injections are not compositionally interchangeable.
The tablets additionally contain folic acid 5 mg, whereas the injectable double ampoule contains B1 + B6 + B12 only.
Important safety update
Because the tablet contains 125 mg of vitamin B6 per tablet, the risk of cumulative vitamin B6 exposure should be explicitly considered. This is an important safety point that was absent from the historical product text.
Current-market status
Current Egyptian market sources continue to list both Tri-B 20 tablets and Tri-B I.M. 3 double ampoules under EL NILE.
Excipient information
The historical leaflet lists excipients for both dosage forms, including lactose and other tablet excipients and benzyl alcohol among the injectable excipients. However, a current manufacturer-confirmed excipient list was not located, so the complete historical excipient list should not be presented as definitively current without checking the latest package leaflet.
21. Frequently Asked Questions (FAQ)
What is Tri-B used for?
Tri-B provides vitamins B1, B6 and B12; the tablet formulation also provides folic acid. Its principal role is vitamin replacement when deficiency or another clinically appropriate indication exists. Historical product information also lists several neurological and hematological conditions.
What is the difference between Tri-B tablets and Tri-B injection?
The tablets contain B1 + B6 + B12 + folic acid, while the double ampoule contains B1 + B6 + B12 and is intended for intramuscular administration.
Is the vitamin B12 in Tri-B tablets 125 mg?
No. The documented tablet strength is 125 micrograms (mcg) of vitamin B12, not 125 mg.
Can Tri-B be taken for a long time?
Long-term unsupervised use is not advisable, particularly with the tablet formulation because it contains 125 mg of vitamin B6 per tablet. Chronic excessive exposure to vitamin B6 can cause peripheral neuropathy.
Can Tri-B be used with levodopa?
Vitamin B6 can reduce the effectiveness of levodopa when levodopa is given without a peripheral decarboxylase inhibitor. Patients receiving levodopa should therefore review the exact treatment regimen with their physician or pharmacist rather than assuming that all levodopa combinations are equivalent.
Does Tri-B treat anemia?
It may be useful when anemia is caused by a deficiency of vitamin B12 or folate, but anemia has many possible causes. The underlying cause should be established before treatment, especially because folic acid can correct the blood abnormalities of B12 deficiency without correcting neurological damage.
Should the two injection ampoules be mixed?
Historical Tri-B instructions state that the contents of Ampoule 1 and Ampoule 2 are mixed and then administered intramuscularly. The current package leaflet should be followed if the formulation or preparation instructions have changed.
22. References
- The NILE Co. / historical Tri-B product information — formulation, dosage form, historical indications, administration and packaging details.
- Current Egyptian market listing — Tri-B I.M. 3 Double Amp — current product name, manufacturer, presentation and active ingredients.
- Current Egyptian pharmacy listing — Tri-B 20 tablets — current product presentation and composition.
- NIH Office of Dietary Supplements — Vitamin B6 Fact Sheet — B6 pharmacology and drug-interaction considerations.
- NIH Office of Dietary Supplements — Vitamin B12 Fact Sheet — B12 absorption, metformin and acid-suppressing drug interactions.
- NIH Office of Dietary Supplements — Folate Fact Sheet — high-dose folic acid, B12 masking and interactions with antiepileptic drugs and sulfasalazine.
- Therapeutic Goods Administration (TGA) — vitamin B6-associated peripheral neuropathy and strengthened safety warnings.
- DailyMed — Thiamine Hydrochloride Injection — parenteral thiamine hypersensitivity and anaphylaxis warnings.
- DailyMed — Cyanocobalamin Injection — intramuscular absorption, distribution, storage and excretion of vitamin B12.
- Egyptian Journal of Surgery — published clinical use documenting the Tri-B tablet composition of B1 125 mg, B6 125 mg, B12 125 mcg and folic acid.
Verification note: The currently accessible evidence supports the core identities, active ingredients and presentations above. A current, complete, manufacturer-issued Tri-B leaflet was not located online during this review; therefore, historical excipient lists and old dosage/indication wording have been explicitly qualified rather than presented as definitively current.